Jakob Höppner

Mr. Jakob Höppner

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2025 in Nature
Verified
Journal Article
Open access
PDF file
GSGayani Senevirathne
Gayani Senevirathne
SFSerena C. Fernandopulle
Serena C. Fernandopulle
DRDaniel Richard
Daniel Richard
SBStephanie L. Baumgart
Stephanie L. Baumgart
ACAnika Liv Christensen
Anika Liv Christensen
TCTerence D. Capellini
Terence D. Capellini
Bipedalism is a human-defining trait1,2,3. It is made possible by the familiar, bowl-shaped pelvis, whose short, wide iliac blades curve along the sides of the body to stabilize walking and support internal organs and a large-brained, broad-shouldered baby4,5,6. The ilium changes compared with living primates are an evolutionary novelty7. However, how this evolution came about remains unknown. Here, using a multifaceted histological, comparative genomic and functional genomic approach, we identified the developmental bases of the morphogenetic shifts in the human pelvis that made bipedalism possible. First, we observe that the human ilium cartilage growth plate underwent a heterotopic shift, residing perpendicular to the orientation present in other primate (and mouse) ilia. Second, we observe heterochronic and heterotopic shifts in ossification that are unlike those in non-human primate ilia or human long bones. Ossification initiates posteriorly, resides externally with fibroblast (and perichondral) cells contributing to osteoblasts, and is delayed compared with other bones in humans and with primate ilia. Underlying these two shifts are regulatory changes in an integrated chondrocyte–perichondral–osteoblast pathway, involving complex hierarchical interactions between SOX9–ZNF521–PTH1R and RUNX2–FOXP1/2. These innovations facilitated further growth of the human pelvis and the unique formation of the ilium among primates.

25 April 2023 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
CGCorinna Grasemann
Corinna Grasemann
JHJakob Höppner
Jakob Höppner
PBPeter Burgard
Peter Burgard
MSMichael Schündeln
Michael Schündeln
NMNora Matar
Nora Matar
DCDaniela Choukair
Daniela Choukair
Purpose: The transition process from paediatric/adolescent to adult medical care settings is of utmost importance for the future health of adolescents with chronic diseases and poses even more difficulties in the context of rare diseases (RDs). Paediatric care teams are challenged to deliver adolescent-appropriate information and structures. Here we present a structured transition pathway which is patient-focused and adoptable for different RDs. Methods: The transition pathway for adolescents 16 years and older was developed and implemented as part of a multi-centre study in 10 university hospitals in Germany. Key elements of the pathway included: assessment of patients’ disease-related knowledge and needs, training/educational and counselling sessions, a structured epicrisis and a transfer appointment jointly with the paediatric and adult specialist. Specific care coordinators from the participating university hospitals were in charge of organization and coordination of the transition process. Results: Of a total of 292 patients, 286 completed the pathway. Deficits in disease-specific knowledge were present in more than 90% of participants. A need for genetic or socio-legal counselling was indicated by > 60%. A mean of 2.1 training sessions per patient were provided over a period of almost 1 year, followed by the transfer to adult care in 267 cases. Twelve patients remained in paediatric care as no adult health care specialist could be identified. Targeted training and counselling resulted in improved disease-specific knowledge and contributed to empowering of patients. Conclusion: The described transition pathway succeeds to improve health literacy in adolescents with RDs and can be implemented by paediatric care teams in any RD specialty. Patient empowerment was mainly achieved by individualized training and counselling.

Verified
Journal Article
Open access
PDF file
JHJakob Höppner
Jakob Höppner
KSKathrin Sinningen
Kathrin Sinningen
ARAdalbert Raimann
Adalbert Raimann
Barbara Obermayer-PietschBarbara Obermayer-Pietsch
Barbara Obermayer-Pietsch
CGCorinna Grasemann
Corinna Grasemann
Familial hypocalciuric hypercalcemia (FHH) is a mostly benign condition of elevated calcium and PTH levels based on a hyposensitive calcium sensing receptor (CaSR) in FHH 1 or its downstream regulatory pathway in FHH2 and FHH3. In children, adolescents and young adults with FHH the main challenge is to distinguish the condition from primary hyperparathyroidism and thereby to avoid unnecessary treatments including parathyroidectomy. However, inheritance of FHH may result in neonatal hyperparathyroidism (NHPT) or neonatal severe hyperparathyroidism (NSHPT), conditions with high morbidity, and in the latter even high mortality. This review focuses on the genetic and pathophysiological framework that leads to the severe neonatal form, gives recommendations for counselling and summarizes treatment options.

28 September 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JHJakob Höppner
Jakob Höppner
VCVincent Casteleyn
Vincent Casteleyn
RBRobert Biesen
Robert Biesen
TRThomas Rose
Thomas Rose
Wolfram WindischWolfram Windisch
Wolfram Windisch
ESElise Siegert
Elise Siegert
Systemic Sclerosis (SSc) is a clinically heterogeneous disease that includes an upregulation of type I interferons (IFNs). The aim of this observational study was to investigate the IFN-regulated protein Sialic Acid–Binding Ig-like Lectin 1 (SIGLEC-1) as a biomarker for disease phenotype, therapeutic response, and differential diagnosis in SSc. Levels of SIGLEC-1 expression on monocytes of 203 SSc patients were determined in a cross-sectional and longitudinal analysis using multicolor flow cytometry, then compared to 119 patients with other rheumatic diseases and 13 healthy controls. SSc patients higher SIGLEC-1 expression on monocytes (2097.94 ± 2134.39) than HCs (1167.45 ± 380.93; p = 0.49), but significantly lower levels than SLE (8761.66 ± 8325.74; p < 0.001) and MCTD (6414.50 ± 1846.55; p < 0.001) patients. A positive SIGELC-1 signature was associated with reduced forced expiratory volume (p = 0.007); however, we were unable to find an association with fibrotic or vascular disease manifestations. SIGLEC-1 remained stable over time and was independent of changes in immunosuppressive therapy. However, SIGLEC-1 is suitable for differentiating SSc from other connective tissue diseases. SIGLEC-1 expression on monocytes can be useful in the differential diagnosis of connective tissue disease but not as a biomarker for SSc disease manifestations or activity.

14 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JHJakob Höppner
Jakob Höppner
HNHiroshi Noda
Hiroshi Noda
AAAnju Krishnan Anitha
Anju Krishnan Anitha
RCRoss Cheloha
Ross Cheloha
TDThomas Dean
Thomas Dean
TGThomas J. Gardella
Thomas J. Gardella
Parathyroid hormone (PTH) analogs with improved actions in vivo could lead to optimized treatments for bone and mineral ion diseases. Rapid clearance from the circulation and short dwell times on the PTH receptor limit the efficacies of conventional PTH peptides currently in medical use. Here, we seek to enhance PTH peptide efficacy using two distinct peptide lipidation strategies. First, we append a lipid chain to the peptide’s C-terminus in a fashion to promote binding to serum albumin and hence prolong the peptide’s circulation half-life in vivo. Second, we append a lipid chain to a lysine side chain in a fashion designed to anchor the peptide to the cell membrane as the ligand is bound to the receptor and hence increase its dwell time on the receptor. We find that both strategies of lipidation can profoundly enhance the efficacy of PTH peptides in vitro and in mice. Our results could lead to the development of modified PTH analogs with optimized therapeutic utility.

3 December 2023 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
ACAdriana Costa
Adriana Costa
AMAndreia Martins
Andreia Martins
CMCatarina Machado
Catarina Machado
ELElena Lundberg
Elena Lundberg
ONOla Nilsson
Ola Nilsson
OMOuti Mäkitie
Outi Mäkitie
Childhood-onset osteoporosis is a rare but clinically significant condition. Studies have shown pathogenic variants in more than 20 different genes as causative for childhood-onset primary osteoporosis. The X-chromosomal PLS3, encoding Plastin-3, is one of the more recently identified genes. In this study, we describe five new families from four different European countries with PLS3-related skeletal fragility. The index cases were all hemizygous males presenting with long bone and vertebral body compression fractures. All patients had low lumbar spine bone mineral density (BMD). The age at the first clinical fracture ranged from 1.5 to 13 years old. Three of the identified PLS3 variants were stop-gain variants and two were deletions involving either a part or all exons of the gene. In four families the variant was inherited from the mother. All heterozygous women reported here had normal BMD and no bone fractures. Four patients received bisphosphonate treatment with good results, showing a lumbar spine BMD increment and vertebral body reshaping after 10 months to 2 years of treatment. Our findings expand the genetic spectrum of PLS3-related osteoporosis. Our report also shows that early treatment with bisphosphonates may influence the disease course and reduce the progression of osteoporosis, highlighting the importance of early diagnosis for prompt intervention and appropriate genetic counseling.